Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 4Advanced Solid Tumors 3Neoplasms 2Advanced Lung Cancer 2Tislelizumab 1Stomach Neoplasms 1Solid Tumor 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1High-Risk Resectable NSCLC 1Colorectal Neoplasms 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Lung Cancer × sintilimab × Clear all
NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡